Sebastien Poulin

Hôpital De St Jérôme, St Jérôme, 
QC, CA 
Hôpital De St Jérôme, St Jérôme, 
QC, CA 

Overview

Sebastien Poulin practices practicing medicine in Canada.

His clinical expertise encompasses Hepatitis D, Hepatitis B, Hepatitis, and Sepsis.

He is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Hôpital De St Jérôme, St Jérôme, QC, Canada
Other Locations
Montreal, QC, Canada
Centre Hospitalier Universitaire Dr. Georges L. Dumont, Vitalité Health Network
Moncton, NB, Canada
Sherbrooke, QC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
Enrollment Status: Terminated
Publish Date: November 13, 2025
Intervention Type: Drug
Study Drug: Fenretinide
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease
A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Biological, Drug
Study Drugs: Otilimab, Standard of Care
Study Phase: Phase 2
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
Enrollment Status: Terminated
Publish Date: June 26, 2024
Intervention Type: Drug
Study Drugs: GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir
Study Phase: Phase 2
A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)
A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)
Enrollment Status: Completed
Publish Date: May 02, 2024
Intervention Type: Drug
Study Drugs: GSK3228836, PegIFN, NA therapy
Study Phase: Phase 2
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
View 4 Less Clinical Trials

15 Total Publications

Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia.
Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia.
Journal: The New England journal of medicine
Published: June 17, 2026

Frequently Asked Questions about Sebastien Poulin

Is Sebastien Poulin a top-rated expert for Hepatitis D?

MediFind is an objective health platform that identifies experts based on real-world data. Sebastien Poulin is classified as an Experienced expert for Hepatitis D, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sebastien Poulin participate in research or clinical trials?

Yes. Sebastien Poulin has published 15 articles and abstracts on conditions like Hepatitis D. You can view a list of Sebastien Poulin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Poulin's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile